14-16 May, 2023 | Convention Centre Dublin | Ireland
We invite you to explore the resources we have assembled below, to demonstrate how we support biotechs and help you meet your critical milestones.
In this blog, discover more about how the biotech sector is transforming uncertainty into opportunity.
Biotechs can hone their pitch with the guidelines provided in this blog and through early engagement opportunities with strategic partners.
Read this blog to learn a few key considerations to help optimise and de-risk your trial design.
Discover how Biotechs can build value into their asset by developing a reimbursable Target Product Profile (rTPP).
The biotechnology sector is leading the way in developing innovative therapies that will address the unmet needs of many challenging diseases.
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.
ICON plc has partnered with ALSA Ventures I SCSp, a Europe focused therapeutic venture capital fund, to accelerate early clinical development within the UK and the EU.
Arrange a meeting with us to discuss your further requirements